Response Genetics to Net $2.2M in Placement of Common Stock | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Response Genetics today said that it will sell 1,175,512 shares of its common stock to certain institutional investors, raising net proceeds of around $2.2 million.

The Los Angeles-based molecular diagnostics firm said that it would sell the shares at a price of $1.99 each through a registered direct offering to certain, unnamed investors. It expects to close the offering tomorrow.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: molecular surveillance of S. Typhi, genome-wide association study of attention in children, and more.

Clinicians look to fold non-medical data into algorithms to predict patients' health, the Wall Street Journal reports.

Connecticut's biotech investment is leading to the building of labs to house new startups, the Associated Press reports.

Craig Venter's Health Nucleus aims to change preventive medicine, according to the Robb Report.